<code id='33DF2AB2DA'></code><style id='33DF2AB2DA'></style>
    • <acronym id='33DF2AB2DA'></acronym>
      <center id='33DF2AB2DA'><center id='33DF2AB2DA'><tfoot id='33DF2AB2DA'></tfoot></center><abbr id='33DF2AB2DA'><dir id='33DF2AB2DA'><tfoot id='33DF2AB2DA'></tfoot><noframes id='33DF2AB2DA'>

    • <optgroup id='33DF2AB2DA'><strike id='33DF2AB2DA'><sup id='33DF2AB2DA'></sup></strike><code id='33DF2AB2DA'></code></optgroup>
        1. <b id='33DF2AB2DA'><label id='33DF2AB2DA'><select id='33DF2AB2DA'><dt id='33DF2AB2DA'><span id='33DF2AB2DA'></span></dt></select></label></b><u id='33DF2AB2DA'></u>
          <i id='33DF2AB2DA'><strike id='33DF2AB2DA'><tt id='33DF2AB2DA'><pre id='33DF2AB2DA'></pre></tt></strike></i>

          Home / fashion / entertainment

          entertainment


          entertainment

          author:knowledge    Page View:935
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In